Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LAM IPM wound gel

This article was originally published in The Gray Sheet

Executive Summary

LAM Pharmaceutical's sodium hyaluronate product, 510(k) cleared April 15, has an 88% effectiveness rate "in creating the necessary environment for wound healing of refractory (hard to heal) leg and foot ulcers," the firm says. The Lewiston, New York firm will launch the gel on June 3. The device is indicated for over-the-counter use on minor abrasions and cuts and for use under the supervision of a health professional for exuding wounds such as leg, pressure and diabetic ulcers...
UsernamePublicRestriction

Register

MT016445

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel